About Annoroad

Annoroad Gene Technology was established in 2012. As a platform-type enterprise in the Chinese genome industry, Annoroad has set up the medical lab in Beijing.

Since its establishment, Annoroad has been honored with the multiple qualifications such as the National High-tech Enterprise, the Pilot Unit for the Clinical Application of the High-throughput Gene Sequencing Technology under National Health Commission, the Demonstration Center for the Application of the Gene Testing Technology under National Development and Reform Commission, the National Intellectual Property Advantage Enterprise,the Laboratory for the Engineering in Beijing, and the Enterprise with the Frontier Technology in Zhongguancun. It boasts a post-doctoral research station.

Annoroad always deeply engages in two major fields, namely, the human medicine & health and the research on the life science, and has set up a professional testing and data analysis platform, to promote the industrialized application of the gene technology initiatively and assist with the development of the life science.

Learn More

Clinical Laboratory

Core Management Team

Xia Zuoquan

Chairman

Mr. Xia Zuoquan, graduating from University of Science and Technology Beijing and Peking University’s Guanghua School of Management, is the angel investor of Annoroad and the co-founder of BYD and acts as the Chairman of Annoroad, the Chairman of Shenzhen Zhengxuan Investment and the Director of BYD now. He, as one of the successful entrepreneurs and investors at home, boasts the rich experience in the multiple fields such as the enterprise governance and the risk control.
Li Zhimin

Chief Executive Officer (CEO)

Mr. Li Zhimin, Senior engineer, MBA from University of Washington, USA, Master of Medicine from Xi’an Medical University; council member of China Healthy Birth Science Association, executive committee member of Beijing Federation of Commerce and Industry, and public supervisor for optimizing business environment in Beijing; titles and honors include: 1st prize of Hubei Science and Technology Achievement Promotion Award in 2021, and “Outstanding Individual of Winter Olympics/Winter Paralympics in Beijing”; 10 SCI papers published and 10 patents granted; former expert member of the National Pharmaceutical Price Evaluation Expert Committee, chair and speaker of medical forums in consecutive years; more than 30 years of management experience in medical and health industry; former general manager or CEO of several renowned listed pharmaceutical companies in China (Conba Pharmaceutical, Buchang Pharmaceuticals, Fosun & Wanbang Pharmaceutical, etc.
Wang Hailiang

Vice President

Mr. Wang Hailiang, graduating from Shandong University (the former Shandong Medical College) where he majored in Pharmaceutics and Peking University’s Guanghua School of Management which awarded an MBA to him, boasts over 20 years of experience in the marketing management in the pharmaceutical industry. He once engaged in the pharmaceutical marketing at Beijing Hospital and MSD (China) and acted as the Vice President of Juneng Pharmaceutical, a former listed company in Hong Kong.